GLP-1 drugs and fracture risk: 21% lower in T2D cohort

GLP-1 drugs and fracture risk: what happened

A UCLA Health study reported that GLP-1 medications were associated with a lower risk of serious fractures in older adults with type 2 diabetes.

The findings were published in JAMA Network Open and were based on electronic health record data comparing new GLP-1 users with new users of DPP-4 inhibitors.

The analysis focused on fragility fractures, which are low-energy fractures often linked to underlying bone weakness, such as after a fall from standing height.

• Study source: UCLA Health; publication: JAMA Network Open (2026)
• Comparison: new GLP-1 receptor agonist users vs new DPP-4 inhibitor users
• Outcome: fragility fracture risk over a three-year period

What the evidence shows about GLP-1 drugs and fracture risk

This was a retrospective observational study using electronic health records from nearly 134,000 U.S. adults ages 50–90 with type 2 diabetes.

Researchers found GLP-1 receptor agonist use was associated with a 21% lower risk of fragility fractures over the three-year study period compared with DPP-4 inhibitor use.

The largest reductions were reported for fractures of the hip, femur, and spine, and a separate analysis linked the reduced risk only with participants who had type 2 diabetes compared with a matched cohort without diabetes.

• Population: U.S. adults ages 50–90 with type 2 diabetes (EHR-based cohort)
• Effect estimate: 21% lower fragility fracture risk vs DPP-4 inhibitor users (association, not proof)
• Where reductions were largest: hip, femur, and spine fractures
• Diabetes-specific signal: reduced risk was associated only with participants with type 2 diabetes in a separate matched-cohort analysis

Why GLP-1 drugs and fracture risk are closely watched in metabolic health

GLP-1 receptor agonists can significantly reduce weight, and there has been debate about whether rapid weight reduction could weaken bones and raise fracture risk.

Adults with type 2 diabetes and obesity are described as having a high risk of fragility fractures, which can have major consequences for mobility and healthy aging.

In that context, the UCLA results add evidence that GLP-1 use, at least in this dataset and comparison group, was linked to lower—not higher—fragility fracture risk.

• Clinical concern addressed: whether weight loss with GLP-1s could worsen bone fragility
• Health impact of the outcome: fragility fractures often stem from bone weakness and can follow low-energy falls
• What this study adds: a large, real-world comparison against another common diabetes drug class (DPP-4 inhibitors)

Practical context: how to use this finding in real-world decisions

This study suggests GLP-1 drugs and fracture risk may be linked in a protective direction for older adults with type 2 diabetes, but it does not establish cause and effect.

For people managing type 2 diabetes, the most practical takeaway is to discuss fracture risk as part of the overall treatment plan, especially when choosing among medication options.

Because fractures are uncommon events, the authors emphasized that very large studies like this one are useful for detecting meaningful differences that smaller studies may miss.

• If you are considering medication options: ask how bone health and fall risk are being factored into the plan
• If you have a history of falls or prior fragility fractures: bring that history into medication discussions
• If you are losing weight on therapy: consider asking how bone health is monitored over time in your care setting

Limits and next questions for GLP-1 drugs and fracture risk

The authors stated the findings come from a retrospective observational study and do not prove that GLP-1s reduce fracture risk.

They called for prospective and translational studies to confirm mechanisms and long-term effects on bone health.

As Dr. Christopher Hamad noted, fractures are relatively uncommon, so large studies are often needed to identify differences that smaller studies cannot detect reliably.

• Study type limitation: observational, retrospective (association only)
• Evidence gaps: mechanism and long-term bone effects need prospective follow-up
• Interpretation caution: the comparison group was DPP-4 inhibitor users, and results may not generalize to every setting or population